TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Folgiero, Valentina ^a   Cifaldi, Loredana ^a   Pira, Giuseppina Li ^a   Goffredo, Bianca Maria ^a   Vinti, Luciana ^a   Locatelli, Franco ^a,b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

AML; Galectin 9; IDO1; Immune escape; NK cells

Indexed keywords

ECALECTIN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERFERON REGULATORY FACTOR 1; MEMBRANE PROTEIN; T LYMPHOCYTE IMMUNOGLOBULIN MUCIN 3; UNCLASSIFIED DRUG; GALECTIN; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; LGALS9 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ACUTE MYELOID LEUKEMIA; BIOSYNTHESIS; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTINS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 85018126461     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0134-4     Document Type: Article

References (12)

1. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245-52. doi:10.1038/ni1271.
2. Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Frontiers Immunology. 2013;4:449. doi:10.3389/fimmu.2013.00449.
3. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272(9):6078-86.
4. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119(13):3064-72. doi:10.1182/blood-2011-06-360321.
5. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7. doi:10.1182/blood-2004-07-2974.
6. Arpinati M, Curti A. Immunotherapy in acute myeloid leukemia. Immunotherapy. 2014;6(1):95-106. doi:10.2217/imt.13.152.
7. Locatelli F, Merli P, Rutella S. At the bedside: innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol. 2013;94(6):1141-57. doi:10.1189/jlb.0613343.
8. Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, et al. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol. 2014;5:95. doi:10.3389/fimmu.2014.00095.
9. Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in immunomodulation and autoimmune disease. Front Immunol. 2014;5:585. doi:10.3389/fimmu.2014.00585.
10. Folgiero V, Goffredo BM, Filippini P, Masetti R, Bonanno G, Caruso R, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 2014;5(8):2052-64.
11. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108(13):4118-25. doi:10.1182/blood-2006-03-006700.
12. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014;27:89-97. doi:10.1016/j.coi.2014.01.002.